Ubs Asset Management Americas Inc Relmada Therapeutics, Inc. Transaction History

Ubs Asset Management Americas Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$18.3 - $37.02 $167,298 - $338,436	9,142 Added 67.57%	22,671 $839,000
Q2 2022 Aug 12, 2022	SELL	$16.5 - $30.34 $174,751 - $321,330	-10,591 Reduced 43.91%	13,529 $256,000
Q1 2022 May 16, 2022	BUY	$16.72 - $26.99 $403,286 - $650,998	24,120 New	24,120 $650,000
Q3 2021 Nov 15, 2021	SELL	$21.86 - $34.77 $160,845 - $255,837	-7,358 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$29.55 - $39.15 $28,308 - $37,505	958 Added 14.97%	7,358 $235,000
Q4 2020 Mar 01, 2021	SELL	$29.88 - $39.8 $164,340 - $218,899	-5,500 Reduced 46.22%	6,400 $205,000
Q3 2020 Nov 13, 2020	BUY	$34.42 - $43.78 $220,288 - $280,192	6,400 Added 116.36%	11,900 $447,000
Q2 2020 Aug 14, 2020	BUY	$31.59 - $49.98 $173,745 - $274,890	5,500 New	5,500 $246,000

12.3M

229K

138K

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $10.9M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

Stay updated on Ubs Asset Management Americas Inc with notifications on news.